ONCOCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.525 USD | +1.81% |
|
+0.60% | +1.00% |
| 25/04 | OncoCyte Corporation announced that it has received $15.8 million in funding | CI |
| 16/04 | Broadwood Capital, Inc. Engages with OncoCyte Corporation | CI |
Chart calendar OncoCyte Corporation
b557cb19f0f382ae6be8.01VatiYDxoSaWpXz4RLAgYoBr0gN4wHHLgD2BUsLy18.gCYdhHYws7HzFuS1ql2H08Ex9nxGhkD3SkSmYx5tijngDz_cUW7_tcg04g~e3a46e6e0488a4fbd96ea7501e2435e5
Upcoming events on OncoCyte Corporation
Past events on OncoCyte Corporation
| 12/04/2024 05:30 pm | Q4 2023 Earnings Call |
| 12/04/2024 03:30 pm | Q4 2023 Earnings Release |
| 25/01/2024 12:00 am | Sequire Investor Summit |
| 09/11/2023 06:30 pm | Q3 2023 Earnings Call |
| 09/11/2023 05:30 pm | Q3 2023 Earnings Release |
| 11/09/2023 04:30 pm | H.C. Wainwright Global Investment Conference |
| 15/08/2023 | Needham Virtual MedTech & Diagnostics Conference |
| 10/08/2023 05:30 pm | Q2 2023 Earnings Call |
| 10/08/2023 04:30 pm | Q2 2023 Earnings Release |
| 21/07/2023 07:30 pm | Extraordinary Shareholders Meeting |
| 23/06/2023 10:30 pm | Annual General Meeting |
| 06/06/2023 10:30 pm | LD Micro Invitational Conference |
| 11/05/2023 06:30 pm | Q1 2023 Earnings Call |
| 11/05/2023 05:30 pm | Q1 2023 Earnings Release |
| 03/04/2023 06:00 pm | Q4 2022 Earnings Call |
| 01/04/2023 02:30 am | Q4 2022 Earnings Release |
| 11/11/2022 03:00 am | Q3 2022 Earnings Call |
| 11/11/2022 03:00 am | Q3 2022 Earnings Release |
| 14/09/2022 | Lake Street Capital Markets Best Ideas Growth Conference |
| 11/08/2022 02:00 am | Interim 2022 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 1,22 1,52 -19.83% | 7,73 7,68 0.68% | 5,60 5,94 -5.72% | 1,50 1,51 -0.66% | 1,45 |
|
EBITDA Million USD | Released Forecast Spread | -21,9 -17,9 -22.32% | -31,6 -27,3 -16.13% | -40,0 -45,4 11.82% | -50,7 -22,8 -122.4% | 0,00 -12,9 - | -3,40 |
|
EBIT Million USD | Released Forecast Spread | -22,2 -19,6 -13.73% | -29,7 -31,3 4.93% | -74,2 -49,7 -49.4% | -72,3 -38,6 -87.47% | -25,1 -16,8 -49.76% | -21,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -22,4 -19,4 -15.53% | -31,2 -32,3 3.38% | -73,4 -49,2 -49.23% | -18,6 -39,0 52.29% | -24,9 -18,0 -38.1% | -21,4 |
|
Net income Million USD | Released Forecast Spread | -22,4 -19,4 -15.53% | -29,9 -31,5 4.87% | -64,1 -40,0 -60.1% | -72,9 -39,2 -85.94% | -28,7 -20,4 -40.98% | -22,1 |
|
EPS USD | Released Forecast Spread | -8,80 -7,60 -15.79% | -9,20 -9,60 4.17% | -14,4 -8,91 -61.54% | -13,2 -7,16 -84.36% | -3,75 -2,50 -50.3% | -2,39 |
| Announcement Date | 25/03/20 | 16/03/21 | 10/03/22 | 31/03/23 | 12/04/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,59 3,52 1.85% | 1,43 2,24 -36.43% | 2,07 2,76 -25.01% | 1,02 1,48 -31.5% | 1,10 1,42 -22.76% | 0,30 0,34 -11.71% | 0,46 0,35 32.29% | 0,43 0,31 37.28% | 0,31 0,32 -0.84% | 0,35 | 0,40 | 0,39 | 0,48 | 0,59 |
|
EBITDA Million USD | Released Forecast Spread | -7,02 -21,1 66.74% | -13,3 -8,90 -49.83% | -9,83 -10,7 7.74% | -13,0 -4,20 -208.33% | -11,1 -4,00 -176.45% | -8,66 -5,40 -60.44% | -5,44 -5,40 -0.7% | -4,72 -2,50 -88.72% | -1,10 | -0,90 | -0,90 | -0,80 | -0,80 | |
|
EBIT Million USD | Released Forecast Spread | -35,7 -11,5 -209.18% | -9,90 -10,9 8.83% | -8,56 -12,6 31.82% | -9,22 -12,6 26.64% | -44,7 -11,0 -305.88% | 2,87 -10,3 127.84% | -8,29 -8,51 2.57% | -6,51 -7,99 18.44% | -16,2 -7,78 -107.92% | -5,34 | -5,37 | -5,35 | -5,43 | -5,36 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -35,8 -11,8 -202.78% | -10,3 -11,1 7.59% | -8,30 -12,8 34.95% | -9,33 -12,8 27.19% | 9,31 -11,1 183.58% | 5,96 -10,2 158.48% | -8,33 -8,30 -0.37% | -6,49 -8,04 19.28% | -13,1 -8,08 -61.77% | -5,31 | -5,37 | -5,35 | -5,40 | -5,31 |
|
Net income Million USD | Released Forecast Spread | -35,9 -11,9 -201.77% | -10,3 -11,2 8.18% | -8,30 -12,8 35.37% | -9,33 -12,9 27.66% | -45,0 -11,2 -300.09% | 3,03 -10,3 129.47% | -8,33 -9,00 7.43% | -6,49 -8,16 20.52% | -16,2 -8,24 -96.45% | -5,47 | -5,53 | -5,51 | -5,56 | -5,31 |
|
EPS USD | Released Forecast Spread | -7,80 -2,54 -206.74% | -2,20 -2,43 9.41% | -1,40 -2,49 43.68% | -1,60 -2,27 29.41% | -8,00 -1,88 -325.53% | 0,40 -1,80 122.22% | -1,07 -1,24 13.57% | -0,81 -1,01 19.6% | -2,07 -0,99 -109.09% | -0,67 | -0,60 | -0,58 | -0,58 | -0,55 |
| Announcement Date | 10/03/22 | 11/05/22 | 10/08/22 | 10/11/22 | 31/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 12/04/24 | - | - | - | - | - |
| Today 01:35 am | EXELIXIS, INC.: Q1 2024 Earnings Release |
| 01/05/2024 | SUMMIT THERAPEUTICS INC.: Q1 2024 Earnings Release |
| 01/05/2024 | MACROGENICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | REGENXBIO INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DECIPHERA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 04:30 pm | NEUROCRINE BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 02/05/2024 01:35 am | SAREPTA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | ZENTALIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | DENALI THERAPEUTICS INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | GERON CORPORATION: Q1 2024 Earnings Release |
Past sector events for OncoCyte Corporation
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- OCX Stock
- Calendar OncoCyte Corporation
